Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr 24:62:124-126.
doi: 10.1016/j.jdcr.2025.04.010. eCollection 2025 Aug.

Topical ruxolitinib in combination with oral minoxidil results in hair regrowth in a patient with central centrifugal cicatricial alopecia and concomitant traction alopecia

Gabriela Soto-Canetti  1 , Hassan Hamade  1 , Benjamin Ungar  1 , Jordan Talia  1
Affiliations
Case Reports

Topical ruxolitinib in combination with oral minoxidil results in hair regrowth in a patient with central centrifugal cicatricial alopecia and concomitant traction alopecia

Gabriela Soto-Canetti et al. JAAD Case Rep. .
No abstract available

Keywords: JAK inhibitors; central centrifugal cicatricial alopecia; ruxolitinib; skin of color; traction alopecia.

PubMed Disclaimer

Conflict of interest statement

Dr Talia has served as a consultant for AbbVie, Arcutis Biotherapeutics, Bristol Myers Squibb, Calliditas Therapeutics, Johnson & Johnson, LEO Pharma, Primus Pharmaceuticals, Sanofi Genzyme, Stifel Financial, and UCB; and has served as an investigator for LEO Pharma and Sanofi. Dr Ungar is an employee of Mount Sinai and has received research funds (grants paid to the institution) from Bristol Myers Squibb, Incyte, Rapt Therapeutics, Pfizer, and Sanofi; and is also a consultant for Arcutis Biotherapeutics, Bristol Myers Squibb, Botanix Pharmaceuticals, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, and UCB. Drs Hamade and Soto-Canetti have no conflicts of interest to disclose.

Figures

Fig 1
Fig 1
Physical examination reveals areas of decreased hair density on scalp vertex (A) and bilateral temporal scalp (B and C). Results after 6 months of topical ruxolitinib show significant hair regrowth on vertex (D) and bilateral temporal scalp (E and F).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Dlova N.C., Salkey K.S., Callender V.D., McMichael A.J. Central centrifugal cicatricial alopecia: new insights and a call for action. J Investig Dermatol Symp Proc. 2017;18(2):S54–S56. doi: 10.1016/j.jisp.2017.01.004. - DOI - PubMed
    1. Roche F.C., Hedberg M.L., Fischer A.S., et al. Activation of STAT3 in lymphocytes associated with central centrifugal cicatricial alopecia. J Am Acad Dermatol. 2023;89(6):1245–1246. doi: 10.1016/j.jaad.2023.01.045. - DOI - PubMed
    1. Nohria A., Desai D., Shapiro J., Bordone L., Lo Sicco K. Review of the use of Janus kinase inhibitors in the treatment of scarring alopecia. Int J Dermatol. 2024;63(6):e105–e110. doi: 10.1111/ijd.17153. - DOI - PubMed
    1. Sood S., Bagit A., Seeburruth D., et al. Janus kinase inhibitor therapy for cicatricial alopecias: an evidence-based review. J Cutan Med Surg. 2024;28(5):505–506. doi: 10.1177/12034754241266153. - DOI - PubMed
    1. Haughton R.D., Herbert S.M., Ji-Xu A., Downing L., Raychaudhuri S.P., Maverakis E. Janus kinase inhibitors for alopecia areata: a narrative review. Indian J Dermatol Venereol Leprol. 2023;89(6):799–806. doi: 10.25259/IJDVL_1093_2022. - DOI - PubMed

Publication types

LinkOut - more resources